DSC
BMY.RT

Duncker Streett & Co’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Duncker Streett & Co’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-4,715
Closed -$3K – 560
2020
Q4 		$3K Buy
4,715
+350
+8% +$746 ﹤0.01% 486
2020
Q3 		$10K Sell
4,365
-150
-3% -$428 ﹤0.01% 436
2020
Q2 		$16K Sell
4,515
-115
-2% -$415 ﹤0.01% 409
2020
Q1 		$18K Sell
4,630
-310
-6% -$1.02K ﹤0.01% 399
2019
Q4 		$15K Buy
+4,940
New +$12.8K ﹤0.01% 444

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Duncker Streett & Co's BMY.RT Position: Q1 2021 in Review

Duncker Streett & Co sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 4,715 shares — an estimated $3K sold.

Duncker Streett & Co first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $18K in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Duncker Streett & Co reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Duncker Streett & Co sold 4,715 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $3K.
  • Duncker Streett & Co first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Duncker Streett & Co's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $18K in Q1 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Duncker Streett & Co's 13F filing for Q1 2021, filed 28 Apr 2021.